RAPID GENERATION OF VACCINES

PRIME has developed a unique, proprietary technology for the generation and manufacturing of new vaccine vectors.

The generation of recombinant poxvectors is considered to be very challenging, costly and time-consuming and represents a major drawback for the use of these viral vectors.

PRIME has eliminated these disadvantages by redefining the generation process. By implementing newest technologies, new recombinant vaccine vector generation could be shortend from formerly half a year to only six weeks. Further, our platform technology is well suited for automated, high throughput manufacturing due to the ease of transgene exchange using the modular brick system. This allows for the development of multivalent vaccines as well as to enter the fields of individualized vaccines and emerging diseases.

A scalable and GMP compliant CMC process allows manufacturing in high quality for human use, while our vaccine products show remarkably high stability characteristics for months even at high temperatures.